NYSE · NVS
Novartis AG
$159.60 +$4.59 (+2.96%) 1D Market open
Session Pulse
Regular session
2
mentions on Wed
· 2 bullish
/ 0 bearish tags
No new SEC filings since Mon close
Full pulse →
Key Metrics
$294.63B
Market cap
21.09×
P/E · TTM
—
Revenue · TTM
$13.97B
Net income
EPS · TTM
$7.35
Dividend yield
—
Free cash flow
—
Beta · 1Y
0.33
EBITDA · TTM
—
Gross margin
—
Snapshot
Market cap$294.63B
Enterprise value—
Shares outstanding1.9B
52-wk range$112.34 – $170.46
Avg volume · 20D1.9M
Net cash
—
Book value / share—
ExchangeNYSE
About Novartis AG
IPO dateNov 7, 1996
Employees75267
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E21.09
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—
Profitability
Gross
—
Operating
—
Net
—
FCF
—
ROE / ROIC
— · —
Financial Health
Current ratio—
Quick ratio—
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital—
Cash Flow · TTM
Operating CF
—
Capex
—
Free cash flow
—
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
0 / 9
Weak fundamentals · 0 of 9 signals passing
Altman Z-Score
—
Insufficient balance-sheet inputs
Graham Number vs Price
—
Requires positive earnings and book value
Fundamentals through 2025-06-30 · computed by TickerWolf from SEC filings